Soligenix (NASDAQ:SNGX) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Soligenix (NASDAQ:SNGX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.05, Zacks reports.

Soligenix Stock Performance

Shares of NASDAQ SNGX traded up $0.00 during midday trading on Friday, reaching $0.34. The stock had a trading volume of 115,354 shares, compared to its average volume of 114,082. The stock has a 50-day moving average of $0.36 and a 200-day moving average of $0.67. The company has a market capitalization of $4.96 million, a price-to-earnings ratio of -0.34 and a beta of 2.04. Soligenix has a 12-month low of $0.28 and a 12-month high of $1.70.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Soligenix Company Profile

Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.

Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.